Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
revusiran
- Development stage
- Discontinued
- Lead developer
- Alnylam Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
- Administration
- Subcutaneous
01
Overview
Revusiran is a first-generation, chemically synthesized double-stranded small interfering RNA (siRNA) therapeutic designed to target transthyretin (TTR) mRNA in the liver, thereby reducing the production of both wild-type and mutant TTR protein. It is conjugated to a triantennary N-acetylgalactosamine (GalNAc) ligand for targeted delivery to hepatocytes via asialoglycoprotein receptors. Revusiran was developed for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), particularly with cardiomyopathy manifestations. The drug demonstrated potent knockdown of serum TTR levels in clinical studies but was discontinued after phase 3 trials due to an imbalance in mortality observed among treated patients compared with placebo[2][3][5][6].
- Other names
- revusiran
02
Targets
TTR (Transthyretin)
Beyond the preview
Go deeper on revusiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on revusiran.